On September 29, 2023, the US Food and Drug Administration (FDA) has published a highly anticipated proposed rule pertaining to laboratory-developed tests (LDTs). This proposed rule, if finalized, would position the FDA to regulate nearly all LDTs as medical devices. Such a development would certainly reshape the legal landscape for corporate legal practitioners in the medical device and healthcare industries.
It’s important to note that this action aligns with the FDA’s longstanding belief that it holds the authority to regulate LDTs as medical devices under the Food, Drug, and Cosmetic Act. Historically, the FDA’s approach to LDT oversight has been one of enforcement discretion. This meant that the agency did not require laboratories that offered such tests to conform to the same regulatory requirements typically associated with the medical device sector.
As this development unfolds, legal professionals are advised to keep abreast of the situation and consider how this potential change could impact their organization or clients. This rule, if finalized, could have significant implications regarding compliance, oversight, and overall operations of businesses in the healthcare industry that handle LDTs.
For more detailed information on this developing rule proposal, you can refer to the original article.